Zahavi David, AlDeghaither Dalal, O'Connell Allison, Weiner Louis M
Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center,3800 Reservoir Rd NW, Washington, DC 20007, USA.
Antib Ther. 2018 Jun 24;1(1):7-12. doi: 10.1093/abt/tby002. eCollection 2018 Jun.
The targeting of surface antigens expressed on tumor cells by monoclonal antibodies (mAbs) has revolutionized cancer therapeutics. One mechanism of action of antibody-based immunotherapy is the activation of immune effector cells to mediate antibody-dependent cell-mediated cytotoxicity (ADCC). This review will summarize the process of ADCC, its important role in the efficacy of mAb therapy, how to measure it, and finally future strategies for antibody design that can take advantage of it to improve clinical performance.
单克隆抗体（mAb）对肿瘤细胞表面表达的抗原进行靶向作用，彻底改变了癌症治疗方法。基于抗体的免疫疗法的一种作用机制是激活免疫效应细胞，以介导抗体依赖性细胞介导的细胞毒性（ADCC）。本综述将总结ADCC的过程、其在单克隆抗体治疗疗效中的重要作用、如何进行检测，以及最终利用ADCC来改善临床疗效的抗体设计未来策略。
